These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8455369)

  • 21. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous alfacalcidol once weekly pulse therapy for secondary hyperparathyroidism in hemodialysis patients.
    El-Shafey EM; Alsahow AE; El-Nagar GF; Ezzat A
    Ren Fail; 2011; 33(3):329-33. PubMed ID: 21401359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients.
    Boudville NC; Hodsman AB
    Nephrol Dial Transplant; 2006 Sep; 21(9):2621-4. PubMed ID: 16644777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parathyroid hormone and platelet cytosolic calcium concentration in essential hypertension.
    Poch E; Fernández-Llama P; Botey A; Gaya J; Darnell A; Rivera F; Revert L
    Nephrol Dial Transplant; 1995; 10(3):366-71. PubMed ID: 7792032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism.
    Lee WT; Padayachi K; Collins JF; Cundy T
    J Am Soc Nephrol; 1994 Dec; 5(6):1344-8. PubMed ID: 7894000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulsatile-secretion of parathyroid hormone in patients with chronic renal failure.
    de Francisco AL; Amado JA; Cotorruelo JG; González M; de Castro SS; Canga E; de Bonis E; Ruiz JC; Arias M; Gonzalez-Macías J
    Clin Nephrol; 1993 Apr; 39(4):224-8. PubMed ID: 8491053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
    Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
    J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
    Koskimies O; Ala-Houhala M
    Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Tvedegaard E; Nielsen PK; Egsmose C; Storm T; Olgaard K
    Am J Nephrol; 1992; 12(5):311-8. PubMed ID: 1488999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alphacalcidol oral pulses normalize uremic hyperparathyroidism prior to dialysis.
    Ala-Houhala M; Holmberg C; Rönnholm K; Paganus A; Laine J; Koskimies O
    Pediatr Nephrol; 1995 Dec; 9(6):737-41. PubMed ID: 8747116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium-regulated parathyroid hormone release in patients with mild or advanced secondary hyperparathyroidism.
    Goodman WG; Belin T; Gales B; Juppner H; Segre GV; Salusky IB
    Kidney Int; 1995 Nov; 48(5):1553-8. PubMed ID: 8544413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure.
    St John A; Thomas MB; Davies CP; Mullan B; Dick I; Hutchison B; van der Schaff A; Prince RL
    Nephron; 1992; 61(4):422-7. PubMed ID: 1501739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The calcitonin-calcium relation curve and calcitonin secretory parameters in renal patients with variable degrees of renal function.
    Messa P; Mioni G; Turrin D; Guerra UP
    Nephrol Dial Transplant; 1995 Dec; 10(12):2259-65. PubMed ID: 8808222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
    Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A
    Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Racial differences in platelet cytosolic calcium and calcitropic hormones in normotensive subjects.
    Brickman AS; Nyby MD; Griffiths RF; von Hungen K; Tuck ML
    Am J Hypertens; 1993 Jan; 6(1):46-51. PubMed ID: 8427661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
    Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
    Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of pulse therapy using 1 alpha(OH)D on secondary hyperparathyroidism in patients on maintenance hemodialysis].
    Yoshida K; Hirayama A; Tanaka N; Yasukawa M; Saka M; Kaneko Y; Maruyama Y; Motomiya Y; Ozono S; Hirao Y
    Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1117-23. PubMed ID: 2287104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease.
    Silver J; Levi R
    Kidney Int Suppl; 2005 Jun; (95):S8-12. PubMed ID: 15882315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.